These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8361646)

  • 21. Huntington's disease: N-methyl-D-aspartate receptor coagonist glycine is increased in platelets.
    Reilmann R; Rolf LH; Lange HW
    Exp Neurol; 1997 Apr; 144(2):416-9. PubMed ID: 9168841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington's Disease Suggests Altered Cell Energetics.
    Singh V; Sharma RK; Athilingam T; Sinha P; Sinha N; Thakur AK
    J Proteome Res; 2017 Oct; 16(10):3863-3872. PubMed ID: 28871787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Huntington's disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma.
    Reilmann R; Rolf LH; Lange HW
    J Neurol Sci; 1994 Dec; 127(1):48-53. PubMed ID: 7699391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea.
    Welch MJ; Markham CH; Jenden DJ
    J Neurol Neurosurg Psychiatry; 1976 Apr; 39(4):367-74. PubMed ID: 132512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.
    Mochel F; Charles P; Seguin F; Barritault J; Coussieu C; Perin L; Le Bouc Y; Gervais C; Carcelain G; Vassault A; Feingold J; Rabier D; Durr A
    PLoS One; 2007 Jul; 2(7):e647. PubMed ID: 17653274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals.
    Manyam NV; Hare TA; Katz L; Glaeser BS
    Arch Neurol; 1978 Nov; 35(11):728-30. PubMed ID: 152621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma amino acid levels in Huntington's chorea.
    Watt JA; Cunningham WL
    Br J Psychiatry; 1978 Apr; 132():394-7. PubMed ID: 147718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cerebrospinal fluid choline levels in patients with Huntington's chorea. Negative effect of haloperidol treatment.
    Consolo S; Ladinsky H; Bianchi S; Caraceni T
    Arch Psychiatr Nervenkr (1970); 1977 May; 223(3):265-70. PubMed ID: 142461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients.
    Kim JS; Kornhuber HH; Holzmüller B; Schmid-Burgk W; Mergner T; Krzepinski G
    Arch Psychiatr Nervenkr (1970); 1980; 228(1):7-10. PubMed ID: 6104477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY1-30 fragment.
    Wagner L; Björkqvist M; Lundh SH; Wolf R; Börgel A; Schlenzig D; Ludwig HH; Rahfeld JU; Leavitt B; Demuth HU; Petersén Å; von Hörsten S
    J Neurochem; 2016 Jun; 137(5):820-37. PubMed ID: 27016395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo imaging of brain glutamate defects in a knock-in mouse model of Huntington's disease.
    Pépin J; Francelle L; Carrillo-de Sauvage MA; de Longprez L; Gipchtein P; Cambon K; Valette J; Brouillet E; Flament J
    Neuroimage; 2016 Oct; 139():53-64. PubMed ID: 27318215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change in the concentrations of amino acids in CSF and serum of patients with essential tremor.
    Málly J; Baranyi M; Vizi ES
    J Neural Transm (Vienna); 1996; 103(5):555-60. PubMed ID: 8811501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioenergetic dysfunction in Huntington's disease human cybrids.
    Ferreira IL; Cunha-Oliveira T; Nascimento MV; Ribeiro M; Proença MT; Januário C; Oliveira CR; Rego AC
    Exp Neurol; 2011 Sep; 231(1):127-34. PubMed ID: 21684277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
    Bender A; Auer DP; Merl T; Reilmann R; Saemann P; Yassouridis A; Bender J; Weindl A; Dose M; Gasser T; Klopstock T
    J Neurol; 2005 Jan; 252(1):36-41. PubMed ID: 15672208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic signatures of Huntington's disease (HD): (1)H NMR analysis of the polar metabolome in post-mortem human brain.
    Graham SF; Kumar PK; Bjorndahl T; Han B; Yilmaz A; Sherman E; Bahado-Singh RO; Wishart D; Mann D; Green BD
    Biochim Biophys Acta; 2016 Sep; 1862(9):1675-84. PubMed ID: 27288730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.
    Jenkins BG; Koroshetz WJ; Beal MF; Rosen BR
    Neurology; 1993 Dec; 43(12):2689-95. PubMed ID: 8255479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CSF-protein patterns in extrapyramidal diseases. Preliminary report with special reference to the protein patterns in Huntington's chorea.
    Kjellin KG; Stibler H
    Eur Neurol; 1974; 12(3):186-94. PubMed ID: 4139015
    [No Abstract]   [Full Text] [Related]  

  • 38. [Amino acids in the blood in Huntington's chorea].
    Oepen H; Oepen I
    Humangenetik; 1965; 1(3):299-302. PubMed ID: 4223837
    [No Abstract]   [Full Text] [Related]  

  • 39. Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea.
    Bonnet AM; Tell G; Schechter PJ; Grove J; Saint-Hilaire MH; De Smet Y; Agid Y
    Mov Disord; 1987; 2(2):117-23. PubMed ID: 2973560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amine metabolites in the cerbrospinal fluid in Huntington's chorea.
    Curzon G; Gumpert J; Sharpe D
    J Neurol Neurosurg Psychiatry; 1972 Aug; 35(4):514-9. PubMed ID: 4261957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.